학술논문
LBA1 Final analysis of the placebo-controlled randomised phase III IMpassion031 trial evaluating neoadjuvant atezolizumab (atezo) plus chemotherapy (CT) followed by open-label adjuvant atezo in patients (pts) with early-stage triple-negative breast cancer (eTNBC)
Document Type
Abstract
Author
Source
In ESMO Open May 2023 8(1) Supplement 4
Subject
Language
ISSN
2059-7029